EUROPE BIOSURGERY MARKET 2019-2027

MARKET OUTLOOK
The Europe biosurgery market is projected to rise at a CAGR of 8.21% throughout the forecasting period of 2019-2027. The U.K., Germany, France and countries in rest of Europe constitute the market for biosurgery in Europe.
The increasing availability of the natural and synthetic sources from which the biosurgical devices are derived is driving the growth of the market. The Gelatin Manufacturers of Europe (GME) was established in 1974. The objective of the GME is to further develop gelatin and hydrolyzed collagen products as well as to open up new markets. Increasing rates of chronic disorders in Europe, including cardiovascular disease, cancer and others is also likely to drive the market for biosurgery.
Increasing rates of pulmonary diseases, renal disorders, and other conditions are progressing toward their severe stages among the U.K. population. As a result, the number of surgical procedures is increasing and this is directly stimulating the demand for biosurgical methodologies in various surgical procedures where patients can lose their lives because of excessive blood loss.
The high cost of surgeries and stringent regulation are major factors obstructing the growth of the biosurgery market in the region. The factors such as rising initiatives of the government for developing bioengineering sector and reimbursement policies and compensation are leveraging the Europe biosurgery market in the coming years. On the other hand, some of the challenges faced by the market in the region are the side-effects & FDA inquiry of the products and complication related to immune response.

COMPETITIVE OUTLOOK
Major players that have established their presence in the biosurgery market include Olympus Corporation, Ypsomed Holding AG, Stryker Corporation, Sanofi, Johnson & Johnson, B. Braun Melsungen AG, Zimmer Biomet Holdings, Inc., Ethicon, Inc., RTI Surgical, Baxter International, Inc., Smith & Nephew Plc, Wright Medical Group N.V. and Medtronic Plc.

TABLE OF CONTENTS
1. BIOSURGERY MARKET - SUMMARY
2. INDUSTRY OUTLOOK
2.1. MARKET DEFINITION
2.2. TRENDS IN BIOSURGERY TECHNOLOGY
2.3. REGULATORY FRAMEWORK
2.4. KEY VENDORS OUTLOOK
2.5. KEY INSIGHT
2.6. KEY BUYING OUTLOOK
2.7. KEY PATENT OUTLOOK
2.8. MARKET DRIVERS
2.8.1. RISE IN SURGICAL TREATMENTS FOR MUSCULOSKELETAL DISORDERS
2.8.2. RISE IN SPINAL FUSION AND JOINT RECONSTRUCTION
2.8.3. INCREASING TRAUMA-RELATED WOUNDS
2.9. MARKET RESTRAINTS
2.9.1. STRINGENT REGULATORY APPROVAL
2.9.2. INCREASE IN THE COST OF SURGERIES
2.9.3. INCREASING USAGE OF MINIMALLY INVASIVE SURGERIES
2.9.4. LACK OF AWARENESS
2.10. MARKET OPPORTUNITIES
2.10.1. DEVELOPMENT OF POLICY FOR REIMBURSEMENT AND COMPENSATION
2.10.2. INCREASE IN RESEARCH AND INVESTMENT IN BIOENGINEERING
2.11. MARKET CHALLENGES
2.11.1. AMPLIFIED SCRUTINY OF STEM CELL-DERIVED PRODUCTS
2.11.2. COMPLICATION RELATED TO IMMUNE RESPONSE
2.11.3. LACK OF SIGNIFICANT DIFFERENTIATION IN THE RANGE OF PRODUCTS
2.11.4. PRODUCT SIDE EFFECTS AND FDA INQUIRY
3. BIOSURGERY MARKET OUTLOOK - BY PRODUCTS
3.1. BONE-GRAFT SUBSTITUTES
3.1.1. SYNTHETIC GRAFT EXTENDER
3.1.2. DEMINERALIZED BONE MATRIX
3.1.3. BONE MORPHOGENETIC PROTEINS
3.1.4. CELL-BASED MATRICES
3.2. HEMOSTATIC AGENTS
3.3. SOFT-TISSUE MANAGEMENT
3.3.1. SYNTHETIC MESH/PATCH
3.3.2. NATURAL MESH/PATCH
3.4. SURGICAL SEALING AGENTS
3.4.1. NATURAL SURGICAL SEALING AGENTS
3.4.2. SYNTHETIC SURGICAL SEALING AGENTS
3.5. ANTI-ADHESIVE AGENTS
4. BIOSURGERY MARKET OUTLOOK - BY APPLICATION
4.1. NEURO AND SPINE SURGERY
4.2. CARDIO AND THORACIC SURGERY
4.3. GENERAL SURGERY
4.4. ORTHOPEDIC SURGERY
5. BIOSURGERY MARKET OUTLOOK - BY SOURCE TYPE
5.1. NATURAL
5.2. SYNTHETIC
6. BIOSURGERY MARKET - REGIONAL OUTLOOK
6.1. EUROPE
6.1.1. COUNTRY ANALYSIS
6.1.1.1. GERMANY
6.1.1.2. THE UNITED KINGDOM
6.1.1.3. FRANCE
6.1.1.4. REST OF EUROPE
7. COMPETITIVE LANDSCAPE
7.1. B. BRAUN MELSUNGEN AG
7.2. JOHNSON & JOHNSON
7.3. BAXTER INTERNATIONAL, INC.
7.4. ETHICON, INC.
7.5. MEDTRONIC PLC
7.6. SANOFI
7.7. OLYMPUS CORPORATION
7.8. RTI SURGICAL
7.9. SMITH & NEPHEW PLC
7.10. STRYKER CORPORATION
7.11. ZIMMER BIOMET HOLDINGS, INC.
7.12. WRIGHT MEDICAL GROUP N.V.
7.13. YPSOMED HOLDING AG
8. METHODOLOGY AND SCOPE
8.1. RESEARCH SCOPE
8.2. SOURCES OF DATA
8.3. RESEARCH METHODOLOGY


TABLE LIST
TABLE 1 EUROPE BIOSURGERY MARKET 2019-2027 ($ MILLION)
TABLE 2 MEDICAL DEVICE CLASSIFICATION
TABLE 3 TYPES OF PMA SUPPLEMENTS
TABLE 4 MEDICAL DEVICES BY CLASS
TABLE 5 EUROPE BIOSURGERY MARKET BY PRODUCTS 2019-2027 ($ MILLION)
TABLE 6 DIFFERENT TYPES OF BONE-GRAFT SUBSTITUTES
TABLE 7 EUROPE BIOSURGERY MARKET IN BONE-GRAFT SUBSTITUTES BY TYPES 2019-2027 ($ MILLION)
TABLE 8 KEY OSTEOBIOLOGIC PRODUCTS AVAILABLE IN THE MARKET
TABLE 9 EUROPE BIOSURGERY MARKET IN HEMOSTATIC AGENTS 2019-2027 ($ MILLION)
TABLE 10 EUROPE BIOSURGERY MARKET IN SOFT-TISSUE MANAGEMENT 2019-2027 ($ MILLION)
TABLE 11 KEY SOFT TISSUE-MANAGEMENT PRODUCTS AVAILABLE IN THE MARKET
TABLE 12 EUROPE BIOSURGERY MARKET IN SOFT-TISSUE MANAGEMENT BY TYPES 2019-2027 ($ MILLION)
TABLE 13 KEY SURGICAL SEALING AGENTS AVAILABLE IN THE MARKET
TABLE 14 EUROPE BIOSURGERY MARKET IN SURGICAL SEALING AGENTS BY TYPES 2019-2027 ($ MILLION)
TABLE 15 EUROPE BIOSURGERY MARKET BY APPLICATIONS 2019-2027 ($ MILLION)
TABLE 16 TYPES OF CARDIOVASCULAR DISEASES
TABLE 17 STAGES OF GRAFT HEALING AND THEIR CHARACTERISTICS TABLE 18 EUROPE BIOSURGERY MARKET BY SOURCE TYPE 2019-2027 ($ MILLION)
TABLE 19 EUROPE BIOSURGERY MARKET BY COUNTRY 2019-2027 ($ MILLION)



FIGURES LIST
FIGURE 1 EUROPE BIOSURGERY MARKET 2019-2027 ($ MILLION)
FIGURE 2 KEY STRATEGIES IN BIOSURGERY MARKET
FIGURE 3 EUROPE PATENT ANALYSIS BY PRODUCT 2010-2016 (%)
FIGURE 4 EUROPE PATENT ANALYSIS BY MARKET PARTICIPANT 2010-2016
FIGURE 5 DIFFERENT TYPES OF NATURAL BIOSURGICAL SEALANTS
FIGURE 6 EUROPE BIOSURGERY MARKET BY BONE-GRAFT SUBSTITUTES 2019-2027 ($ MILLION)

FIGURE 7 EUROPE BONE-GRAFT SUBSTITUTES MARKET BY SYNTHETIC GRAFT EXTENDERS 2019-2027 ($ MILLION)

FIGURE 8 EUROPE BONE-GRAFT SUBSTITUTES MARKET BY DEMINERALIZED BONE MATRIX 2019-2027 ($ MILLION)

FIGURE 9 EUROPE BONE-GRAFT SUBSTITUTES MARKET BY BONE MORPHOGENETIC PROTEINS 2019-2027 ($ MILLION)

FIGURE 10 EUROPE BONE-GRAFT SUBSTITUTES MARKET BY CELL-BASED MATRICES 2019-2027 ($ MILLION)

FIGURE 11 EUROPE BIOSURGERY MARKET BY HEMOSTATIC AGENTS 2019-2027 ($ MILLION)
FIGURE 12 EUROPE BIOSURGERY MARKET BY SOFT-TISSUE MANAGEMENT 2019-2027 ($ MILLION)

FIGURE 13 EUROPE BIOSURGERY MARKET IN SOFT-TISSUE MANAGEMENT 2019-2027 ($ MILLION)

FIGURE 14 EUROPE SOFT-TISSUE MANAGEMENT MARKET BY SYNTHETIC MESHES 2019-2027 ($ MILLION)

FIGURE 15 EUROPE BIOSURGERY MARKET BY SURGICAL SEALING AGENTS 2019-2027 ($ MILLION)

FIGURE 16 EUROPE SURGICAL SEALING AGENTS MARKET BY NATURAL 2019-2027 ($ MILLION)

FIGURE 17 EUROPE SURGICAL SEALING AGENTS MARKET BY SYNTHETIC 2019-2027 ($ MILLION)

FIGURE 18 EUROPE BIOSURGERY MARKET IN ANTI-ADHESIVE AGENTS 2019-2027 ($ MILLION)

FIGURE 19 EUROPE BIOSURGERY MARKET BY NEURO AND SPINE SURGERY 2019-2027 ($ MILLION)

FIGURE 20 EUROPE BIOSURGERY MARKET BY CARDIO AND THORACIC SURGERY 2019-2027 ($ MILLION)

FIGURE 21 EUROPE BIOSURGERY MARKET BY GENERAL SURGERY 2019-2027 ($ MILLION)

FIGURE 22 EUROPE BIOSURGERY MARKET BY ORTHOPEDIC SURGERY 2019-2027 ($ MILLION)

FIGURE 23 EUROPE BIOSURGERY MARKET BY NATURAL 2019-2027
FIGURE 24 EUROPE BIOSURGERY MARKET BY SYNTHETIC 2019-2027
FIGURE 25 EUROPE BIOSURGERY MARKET 2019-2027 ($ MILLION)
FIGURE 26 RATE OF CHRONIC DISORDERS IN EUROPE 2016 (%)
FIGURE 27 GERMANY BIOSURGERY MARKET 2019-2027 ($ MILLION)
FIGURE 28 THE UNITED KINGDOM BIOSURGERY MARKET 2019-2027 ($ MILLION)

FIGURE 29 FRANCE BIOSURGERY MARKET 2019-2027 ($ MILLION)
FIGURE 30 REST OF EUROPE BIOSURGERY MARKET 2019-2027 ($ MILLION)